On Invalid Date, Cidara Therapeutics (NASDAQ: CDTX) reported Q3 2023 earnings per share (EPS) of -$0.09, up 152.94% year over year. Total Cidara Therapeutics earnings for the quarter were -$8.17 million. In the same quarter last year, Cidara Therapeutics's earnings per share (EPS) was $0.17.
As of Q4 2023, Cidara Therapeutics's earnings has grown year over year. Cidara Therapeutics's earnings in the past year totalled -$31.37 million.
What was CDTX's revenue last quarter?
On Invalid Date, Cidara Therapeutics (NASDAQ: CDTX) reported Q3 2023 revenue of $12.72 million up 68.79% year over year. In the same quarter last year, Cidara Therapeutics's revenue was $40.74 million.
What was CDTX's revenue growth in the past year?
As of Q4 2023, Cidara Therapeutics's revenue has grown -7.75% year over year. This is 118.33 percentage points lower than the US Biotechnology industry revenue growth rate of 110.58%. Cidara Therapeutics's revenue in the past year totalled $56.54 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.